3 Pieces of Advice for Patient Advocacy Groups Participating in Canada’s Drug Review Process
Recently, Novo Nordisk announced that Rebinyn (Coagulation Factor IX (Recombinant), pegylated), was 1 of 5 drugs that will be available for patients in Canada with hemophilia B. Making those drugs available in Canada was dependent on patients’ input into the value those treatments brings to the hemophilia B community.
Read More